BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes plc Reports First Quarter 2026 Financial Results

Alkermes plc (ALKS)Alkermes plcEarnings

DUBLIN --(BUSINESS WIRE)--May 5, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company’s

Open original release

Related news

ALKSAlkermes plc2026-04-21 20:05 EST

Alkermes to Report First Quarter Financial Results on May 5, 2026

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

ABOSAcumen Pharmaceuticals2026-05-12 11:00 EST

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

ANNXAnnexon, Inc.2026-05-07 20:01 EST

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

PRAXPraxis Precision Medicines2026-05-07 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-05-07 11:00 EST

Xeris Biopharma Reports First Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-05-06 12:00 EST

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

NBIXNeurocrine Biosciences2026-05-05 20:01 EST

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-06-04 11:00 EST

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ALKSAlkermes plc2026-05-26 11:00 EST

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

ALKSAlkermes plc2026-05-21 11:00 EST

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

ALKSAlkermes plc2026-05-12 11:00 EST

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Stock data

Close
52.73 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States